Table 1.

Clinical, genetic, and IFD characteristics in the GATA2 Cohort

Patient ID	Age, y	Disease/treatment			GATA2			IFD
		Diagnosis	HCT	Proximal chemotherapy	Mutation	VAF	Somatic confidence	Category	Infection site	Mycology	ANC <0.5 × 103/μL
G1	51	AML	Yes	MEC	N317H	0.12	Definite	Proven	Brain	Pathology with invasive fungal forms, culture with Scedosporium sp.	Yes
G2	68	AML	No	MEC	R398W	0.30	Definite	Proven	Pulmonary, disseminated candidiasis	Elevated serum galactomannan, C tropicalis bloodstream infection	Yes
G3	58	MDS	Yes	—	R398W	0.37	Definite	Proven	Pulmonary, disseminated candidiasis	Elevated serum galactomannan, C albicans bloodstream infection	Yes
G4	72	AML	Yes	—	G320D	0.37	Likely	Proven	Disseminated candidiasis	C tropicalis bloodstream infection	Yes
G5	51	MDS/MPN	Yes	—	R396Q	0.08	Definite	Proven	Pulmonary	Pathology with invasive fungal forms, BAL culture with Rhizopus sp.	No
G6	49	AML	Yes	Decitabine	G320D	0.44	Definite	Probable	Sinus	Elevated serum galactomannan	Yes
G7	70	AML	Yes	Clofarabine, cytarabine	T301K	0.31	Definite	Probable	Pulmonary	Elevated serum β-d-glucan	Yes
G8	35	AML	Yes	Decitabine	L321P	0.16	Definite	Probable	Pulmonary	BAL culture with A fumigatus	Yes
G9	53	AML	Yes	MEC	A12fs*	0.44	Definite	Probable	Pulmonary	Elevated BAL galactomannan	Yes
G10	68	AML	No	CPX-351	M388_K390del	0.31	Definite	Probable	Pulmonary	Elevated serum β-d-glucan	Yes
G11	63	AML	No	Decitabine/venetoclax	G320D	0.41	Likely	Probable	Pulmonary	Elevated serum galactomannan	Yes
G12	61	MDS	No	CPX-351	G82fs*	0.08	Definite	Probable	Pulmonary	Elevated serum β-d-glucan	Yes
G13	50	AML	Yes	—	N297S	0.45	Likely	Probable	Pulmonary	Elevated serum galactomannan/β-d-glucan	Yes
G14	68	MDS/MPN	Yes	Decitabine	P385R	0.13	Definite	Probable	Pulmonary	BAL culture with A fumigatus	No
G15	62	AML	Yes	—	V16fs*	0.38	Definite	Probable	Pulmonary	Elevated serum β-d-glucan	Yes
G16	54	AML	No	αCD123 ADC	K282fs*	0.21	Definite	Possible-treated	Pulmonary	—	Yes
G17	66	AML	No	Daunorubicin, cytarabine	T354M, P121fs*	0.44, 0.36	Definite	Possible-treated	Pulmonary	—	Yes
G18	66	AML	No	Daunorubicin, cytarabine	D99fs*	0.18	Definite	Possible-treated	Pulmonary	—	Yes
G19	70	AML	No	MEC	M388_E391del	0.44	Definite	Possible-treated	Pulmonary	—	Yes
G20	55	AML	No	Daunorubicin, cytarabine	G274fs*	0.13	Definite	Possible-treated	Pulmonary	—	Yes
G21	43	MDS/MPN	Yes	—	L321F	0.15	Definite	Possible-treated	Pulmonary	—	Yes

αCD123-ADC, αCD123-targeting antibody-drug conjugate; ANC, absolute neutrophil count; MEC, mitoxantrone, etoposide, and intermediate-dose Ara-C; VAF, variant allele frequency (VAF at initial index detection).